Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap

Robert Lee Page II1 School of Pharmacy, Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO;2 School of Medicine, Department of Physical Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO

Vahram Ghushchyan1 School of Pharmacy, Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO

Richard R Allen3 Peakstat Statistical Services, Evergreen, CO

Lisa Roper4 Universal American, Houston, TX

Don Beck4 Universal American, Houston, TX

Bamrom H Jonathan4 Universal American, Houston, TX

Feride Frech-Tamas5 Novartis Pharmaceuticals, East Hanover, New Jersey, USA

Wing Chan5 Novartis Pharmaceuticals, East Hanover, New Jersey, USA

R Brett McQueen1 School of Pharmacy, Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, CO

Kavita V Nair1 School of Pharmacy, Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, COCorrespondencekavita.nair@ucdenver

show all

Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Costs and outcomes associated with clopidogrel discontinuation in Medicare beneficiaries with acute coronary syndrome in the coverage gap

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date